New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg
The model's full reasoning — Q1 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否表示新业务的经济条款(价格、费率、费用、利差、合同规模、期限或盈利能力)相比公司自身近期常态有显著提升,并且这种改善才刚刚开始反映在报告业绩中,因为报告中的大部分业务仍以旧的、较不利的条款成交。 分析电话会议内容: - 管理层讨论了ModeX收购、Sema4交易、Pfizer里程碑付款等,但这些是交易或一次性事件,不是持续的业务条款改善。 - 关于BioReference实验室,Jon Cohen提到核心临床业务量增长4%,非侵入性产前检测增长219%,肿瘤业务增长5%等,但这些都是数量增长,没有提到价格或费率改善。 - 提到4Kscore测试获得FDA批准,计划获得更多商业保险覆盖,但这是未来计划,不是已实现的条款改善。 - 提到Scarlet Health获得更多报销,但未具体说明费率提高。 - 关于成本削减计划(Reach)旨在降低成本,但这是成本控制,不是收入条款改善。 - 关于Somatrogon,提到Pfizer在德国和日本推出,触发8500万美元里程碑付款,但这是里程碑,不是持续业务条款。 - 没有明确提到新合同、续约或新业务的价格、费率、利差等相比过去有显著改善,并且这种改善尚未完全反映在业绩中。 因此,管理层没有描述新业务条款的改善,也没有提到改善刚开始流入报告结果。所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| MTB | M&T Bank Corporation | Q2 2022 | 2022-07-20 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...